Results 311 to 320 of about 16,748,637 (363)

PDE10A as a novel diagnostic and therapeutic target in cancer: insights and challenges. [PDF]

Front Oncol
Ghoflchi S, Nakhaei A, Abbasinezhad-Moud F, Jalili-Nik M, Cimino PJ.   +4 more
europepmc   +1 more source

Direct-to-Consumer Erectile Dysfunction Medications: is the Convenience Worth the Cost? [PDF]

Curr Urol Rep
Li MK, Patel DP, Hsieh TC.
europepmc   +1 more source

Preclinical studies of the effects of a drug based on ethylmethylhydroxypyridine succinate and a phosphodiesterase-3 inhibitor on laboratory animals

I. S. Varkholiak, B. V. Gutyj, D. F. Gufrij, L. P. Horalskyi, Roman Mylostyvyi, T. V. Martyshuk, Kh. Ya. Leskiv, У. М. Вус, O. O. Dashkovskyi, Olena Izhboldina, V. P. Prysyazhnyuk, S. S. Adamiv   +11 more
openalex   +2 more sources

Pulmonary Arterial Hypertension: Recognition and Management in Primary and Acute Care Settings. [PDF]

Cureus
Ahern BJ, Fulford ST, Long D, Miller CL.
europepmc   +1 more source

40P Ectonucleotide pyrophosphate/phosphodiesterase 3 (ENPP3) expression selects distinct transcriptional clusters in metastatic renal cell carcinoma (mRCC)

V. Abreu de Goes, N.J. Salgia, Y.J. Li, K. Shah, M. Zugman, S. Jaime-Casas, B. Mercier, D. Castro, R. Barragan-Carrillo, X. Li, H. Ebrahimi, R. Agarwal, J. Hsu, A. Chehrazi-Raffle, S.K. Pal   +14 more
openalex   +1 more source

Identification of biomarkers of Shenhailong formula in benign prostatic hyperplasia treatment: An observation study using network pharmacology and Mendelian randomization analysis. [PDF]

Medicine (Baltimore)
Pan J, Yu M, Zhang L, Yin J, Liu J, Zhang S, Zhang P, Fan Q, Liu J, Li X.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The dual phosphodiesterase 3/4 inhibitor RPL554 stimulates rare class III and IV CFTR mutants.

American Journal of Physiology - Lung cellular and Molecular Physiology, 2020
Over 2,000 mutations have been reported in the cftr gene, many of which cause disease but are rare and have no effective treatment. Thus, there is an unmet need for new, mutation-agnostic, therapies for cystic fibrosis (CF).
M. Turner, Yishan Luo, David Y. Thomas, J. Hanrahan   +3 more
semanticscholar   +1 more source

Pulmonary Responses to Selective Phosphodiesterase-5 and Phosphodiesterase-3 Inhibitors

Chest, 2004
To compare the direct pulmonary vasodilating activity and specificity of phosphodiesterase-5 (zaprinast) and phosphodiesterase-3 (milrinone) inhibitors on the pulmonary vascular (PV) bed of the spontaneously breathing cat with an intact chest.Prospective, randomized animal study.Laboratory of university hospital.Experiments were performed in vivo in ...
Idit, Matot, Yaacov, Gozal
openaire   +2 more sources

Tyrosyl‐DNA Phosphodiesterase (Tdp1) (3′‐Phosphotyrosyl DNA Phosphodiesterase)

2006
Tyrosyl-DNA phosphodiesterase (Tdp1) hydrolyzes 3'-phosphotyrosyl bonds in vitro. Because topoisomerase I, a type IB topoisomerase, is the only enzyme known to form 3'-phosphotyrosine bonds in eukaryotic cells, it was proposed that Tdp1 is involved in the repair of dead-end topoisomerase I-DNA covalent complexes that may form in vivo.
Amy C, Raymond, Alex B, Burgin
openaire   +2 more sources

Purification of Rat 2′,3′‐Cyclic Nucleotide 3′‐Phosphodiesterase

Journal of Neurochemistry, 1981
Abstract: 2′,3′‐Cyclic nucleotide 3′‐phosphodiesterase (CNP, EC 3.1.4.37) has been isolated from rat brain myelin by chromatography on successive columns of phenyl‐Sepharose CL‐4B, CM‐Sepharose CL‐6B, and 8‐(6‐aminohexyl) amino‐2′AMP‐Sepharose 4B. From 15 g of rat brain, approximately 400 μg of pure CNP was obtained, with a specific activity of 1.200 (
M R, Wells, T J, Sprinkle
openaire   +2 more sources